ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has entered into a lucrative license and collaboration agreement with SynBioTx Inc., granting exclusive rights outside the Greater China Region for researching, developing, and commercializing its bispecific antibodies IMM2510 and monoclonal antibodies IMM27M. The company retains rights within Greater China and stands to receive up to $50 million in upfront and near-term payments, $2.1 billion in potential milestone payments, and royalties on global net sales. This strategic partnership aims to expand ImmuneOnco’s global reach and maximize the value of its technology platforms.
For further insights into HK:1541 stock, check out TipRanks’ Stock Analysis page.
